Pharmacokinetics and safety of dolutegravir in term neonates exposed to HIV-1 (IMPAACT 2023): a phase 1, open-label, multicentre study.
BACKGROUND Safe and effective antiretroviral options are needed for neonates exposed to HIV-1, but data supporting dolutegravir use from birth are scarce. The aim of this study was to evaluate dolutegravir pharmacokinetics, safety, and tolerability in term neonates, and to identify an appropriate dosing regimen. METH...